COMMUNIQUÉS West-GlobeNewswire

BioSyent Announces Renewal of Normal Course Issuer Bid
15/12/2025
MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of [...]
Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier
15/12/2025
NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour [...]
Cellectis Announces Arbitral Decision in Dispute with Servier
15/12/2025
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
XOMA Royalty Enters into Agreement to Acquire Generation Bio
15/12/2025
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for [...]
Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
15/12/2025
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly [...]
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
15/12/2025
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the [...]
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
15/12/2025
Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, [...]
AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers
15/12/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR BIORXIV QUI IDENTIFIE ET CARACTÉRISE UNE NOUVELLE MOLÉCULE SYNTHÉTIQUE, AB8939, COMME UN CANDIDAT MÉDICAMENT PROMETTEUR POUR LE TRAITEMENT DE LA [...]
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
15/12/2025
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA ( [...]
Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
15/12/2025
Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and [...]
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
15/12/2025
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation , today announced the publication of a peer-reviewed research article [...]
Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai
15/12/2025
The Visionary Surgeon Who Uses Face Art Techniques to Sculpt Faces, Ensuring Timeless Harmony and Profound Confidence DUBAI, United Arab Emirates, Dec. 15, 2025 (GLOBE NEWSWIRE) -- In Dubai, Dr. Jaffer Khan is [...]
Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients
15/12/2025
Langenfeld, Germany, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Booking Health , a leading platform for international medical travel, announced today the release of its 2026 rankings of Germany’s most trusted cancer hospitals. [...]
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques
15/12/2025
PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des [...]
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
15/12/2025
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno- [...]
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
15/12/2025
Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products [...]
Jade Biosciences Announces $45 Million Private Placement
15/12/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
15/12/2025
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent brain metastases [...]
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
15/12/2025
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib [...]

Pages